MichaelFPressMD
Pathology • Los Angeles, CAAnatomic Pathology, Clinical Pathology
Professor, Pathology, USC School of Medicine
Dr. Press is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1441 Eastlake Ave
Los Angeles, CA 90089Phone+1 323-442-2582Fax+1 323-865-0122
Education & Training
University of ChicagoResidency, Pathology-Anatomic and Clinical, 1977 - 1981
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1977
University of ChicagoPh.D., Cell Biology , 1970 - 1975
Certifications & Licensure
CA State Medical License 1988 - 2026
FL State Medical License 2015 - 2026
IL State Medical License 1978 - 2026
NC State Medical License 2015 - 2025
NV State Medical License 2012 - 2025
ID State Medical License 2012 - 2022- American Board of Pathology Anatomic Pathology
Publications & Presentations
PubMed
- 33 citationsEvaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.Zhaohui Du, Guimin Gao, Babatunde Adedokun, Thomas U. Ahearn, Kathryn L. Lunetta
Journal of the National Cancer Institute. 2021-09-04 - 127 citationsThe NICHD Women's Contraceptive and Reproductive Experiences Study: Methods and operational resultsPolly A. Marchbanks, Jill A. McDonald, Hoyt G. Wilson, Nancy M. Burnett, Janet R. Daling
Annals of Epidemiology. 2002-05-01 - 3302 citationsAmerican society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerAntonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz, Karen L. Hagerty, D. Craig Allred
Journal of Clinical Oncology. 2006-01-20
Journal Articles
- RNA-Seq of Circulating Tumor Cells in Stage II–III Breast CancerMichael F Press, Julie E Lang, Annals of Surgical Oncology
Press Mentions
AR Emerges as a Potential Target in Triple-Negative Breast CancerMarch 24th, 2017- HER2 Gene Testing Guidelines May Misclassify PatientsMarch 13th, 2017
- Expert Sheds Light on Issues with ASCO-CAP HER2 GuidelinesSeptember 27th, 2016
- Join now to see all
Grant Support
- Pathobiology Of Breast Cancer And Hormone ReceptorsNational Cancer Institute1988–2003
- Pilot--Breast CancerNational Cancer Institute2001–2002
- HER-2 NEU Proto-Oncogene In Ovarian &Endometrial CancerNational Cancer Institute1991–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
